Last week's top five stocks that were bought by their CEOs were Advanced Battery Technologies Inc (ABAT, Financial), Spectrum Pharmaceuticals Inc (SPPI, Financial), Bruker BioSciences Corp (BRKR, Financial), and Verizon Communications Inc (VZ, Financial) and Angiotech Pharmaceuticals Inc. (ANPI, Financial). According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
Advanced Battery Technologies Inc. (ABAT): CEO, 10% Owner Zhiguo Fu Bought 1,000,000 Shares
CEO, 10% Owner of Advanced Battery Technologies Inc. (ABAT) Zhiguo Fu bought 1,000,000 shares on 05/04/2009 at an average price of $3.73. Advanced Battery Technologies develops manufactures and distributes rechargeable PLI battery cells using lithium cobalt oxide anodes to overcome many of the shortcomings associated with other types of rechargeable batteries. The company has a market cap of $203.9 million; its shares were traded at around $3.73 with a P/E ratio of 12 and P/S ratio of 4.5.
No other insiders except for its CEO have recently traded in the company.
Spectrum Pharmaceuticals Inc. (SPPI): Chairman, CEO & President Rajesh C Md Shrotriya Bought 290,000 Shares
Chairman, CEO & President of Spectrum Pharmaceuticals Inc. (SPPI) Rajesh C Md Shrotriya bought 290,000 shares on 05/06/2009 at an average price of $3.66. Spectrum Pharmaceuticals Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. The company has a market cap of $117.7 million; its shares were traded at around $3.66 with and P/S ratio of 4.2.
Buy: Vice President Finance Shyam K Kumaria bought 85,000 shares of SPPI stock on 05/06/2009 at the average price of $2.7; the price of the stock has increased by 35.56% since.
Bruker BioSciences Corp. (BRKR): CEO/President, 10% Owner Frank H Laukien Bought 100,000 Shares
CEO/President, 10% Owner of Bruker BioSciences Corp. (BRKR) Frank H Laukien bought 100,000 shares on 05/07/2009 at an average price of $7.29. As of February 26, 2008 the renamed BRUKER CORPORATION has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group Bruker Corporation now operates in two segments the life science and analytical (LSA) systems segment and the international advanced superconductor (IAS) segment. Bruker has a market cap of $1.2 billion; its shares were traded at around $7.29 with a P/E ratio of 15.5 and P/S ratio of 1.1.
Bruker recently reported its first quarter 2009 results. The company announced that its xGAAP net income for the first quarter of 2009 was $8.4 million, or 5 cents per diluted share, compared to a net loss of ($0.8) million, or 0 cents per diluted share, in the first quarter of 2008. Frank Laukien, President and CEO, commented: “We are pleased with our first quarter 2009 results, given the challenges in the marketplace today. During the first quarter, while we saw softness in our industrial and pharma/biotech orders, we recorded healthy orders from academic, medical school, government and other non-profit customers, which typically account for about two-thirds of Bruker’s revenue. While we continue to be below our gross margin and operating margin goals, we have started to see the effects of our cost-cutting initiatives and we expect to realize further savings in 2009. We continue to rationalize our cost structure, but we also are investing in new opportunities, and have introduced a record number of important new products so far in 2009.”
Bruker's CFO increased his position in the company, while another insider lowered his. CFO William J Knight bought 5,000 shares of BRKR stock on 11/20/2008 at the average price of $3.73. 10% Owner Marc M Laukien sold 2,100,000 shares of BRKR stock on 05/07/2009 at the average price of $6.91; the price of the stock has increased by 5.5% since.
Verizon Communications Inc. (VZ): EVP and Pres. & CEO - VZW JV Lowell C Mcadam Bought 16,700 Shares
EVP and Pres. & CEO - VZW JV of Verizon Communications Inc. (VZ) Lowell C Mcadam bought 16,700 shares on 05/06/2009 at an average price of $29.85. Verizon Communications formed by the merger of Bell Atlantic and GTE is one of the world's leading providers of high-growth communications services. Verizon companies are the largest providers of wireline and wireless communications in the United States. Verizon is also the world's largest provider of print and on-line directory information. Verizon Communications Inc. has a market cap of $84.77 billion; its shares were traded at around $29.85 with a P/E ratio of 11.6 and P/S ratio of 0.9. The dividend yield of Verizon Communications Inc. stocks is 6.2%. Verizon Communications Inc. had an annual average earning growth of 2.4% over the past 10 years. GuruFocus rated Verizon Communications Inc. the business predictability rank of 4-star.
Verizon recently reported its 1 st quarter 2009 results. The company announced that its diluted earnings per share was 58 cents per share, compared to 57 cents per share a year ago. The company's total revenues grew 11.6%. "Our business groups executed with excellence in the first quarter," said Verizon Chairman and CEO Ivan Seidenberg. "Our operational and financial discipline produced continued revenue and earnings growth, as well as an expansion of our already strong operating cash flows. A highlight of the quarter was our successful completion of the Alltel acquisition. We quickly began integration efforts, and we are aggressively pursuing synergies."
Brian Rogers owns 5,223,000 shares as of 03/31/2009. Tweedy Browne owns 11,418 shares as of 12/31/2008. Kenneth Fisher owns 581,660 shares as of 12/31/2008, a decrease of 25.96% of from the previous quarter. Mark Hillman owns 573,251 shares as of 12/31/2008, a decrease of 33.47% of from the previous quarter. Richard Aster Jr owns 626,000 shares as of 03/31/2009, a decrease of 39.95% of from the previous quarter. George Soros owns 10,000 shares as of 12/31/2008, a decrease of 75% of from the previous quarter.
Two other insiders have also increased their positions in the company. EVP & Chief Technology Officer Richard J. Lynch bought 2,000 shares, while President of Verizon Business John F Killian bought 7,500 shares of VZ stock.
Angiotech Pharmaceuticals Inc. (ANPI): President & CEO William L Hunter Bought 634,551 Shares
President & CEO of Angiotech Pharmaceuticals Inc. (ANPI) William L Hunter bought 634,551 shares during the past week at an average price of $0.68. Angiotech Pharmaceuticals Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of the anticancer drug paclitaxel. The company has a market cap of $58 million; its shares were traded at around $0.68 with and P/S ratio of 0.2.
Angiotech Pharmaceuticals recently reported its first quarter 2009 results. The company announced that its total revenue was $88.3 million, and net product sales were $46.1 million. “We were pleased to post solid results for our first quarter in what has been a difficult business environment for many companies,” said Dr. William Hunter, President and CEO of Angiotech. “Sales in our proprietary Surgical and Interventional business areas continued to show very promising growth, with Quill SRS in particular garnering greater acceptance in new hospitals and surgical disciplines, and we continued to realize
expense reductions as compared to the prior quarter. Additionally, our royalty revenue increased as compared to the fourth quarter of last year, indicating an improved market position for our partner Boston Scientific and higher sales of paclitaxel-eluting stents.”
Other insiders are increasing their positions in the company, including 10% Owner Coast Asset Management In West, Director Hartley T Richardson, and Director David T Howard
Advanced Battery Technologies Inc. (ABAT): CEO, 10% Owner Zhiguo Fu Bought 1,000,000 Shares
CEO, 10% Owner of Advanced Battery Technologies Inc. (ABAT) Zhiguo Fu bought 1,000,000 shares on 05/04/2009 at an average price of $3.73. Advanced Battery Technologies develops manufactures and distributes rechargeable PLI battery cells using lithium cobalt oxide anodes to overcome many of the shortcomings associated with other types of rechargeable batteries. The company has a market cap of $203.9 million; its shares were traded at around $3.73 with a P/E ratio of 12 and P/S ratio of 4.5.
No other insiders except for its CEO have recently traded in the company.
Spectrum Pharmaceuticals Inc. (SPPI): Chairman, CEO & President Rajesh C Md Shrotriya Bought 290,000 Shares
Chairman, CEO & President of Spectrum Pharmaceuticals Inc. (SPPI) Rajesh C Md Shrotriya bought 290,000 shares on 05/06/2009 at an average price of $3.66. Spectrum Pharmaceuticals Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. The company has a market cap of $117.7 million; its shares were traded at around $3.66 with and P/S ratio of 4.2.
Buy: Vice President Finance Shyam K Kumaria bought 85,000 shares of SPPI stock on 05/06/2009 at the average price of $2.7; the price of the stock has increased by 35.56% since.
Bruker BioSciences Corp. (BRKR): CEO/President, 10% Owner Frank H Laukien Bought 100,000 Shares
CEO/President, 10% Owner of Bruker BioSciences Corp. (BRKR) Frank H Laukien bought 100,000 shares on 05/07/2009 at an average price of $7.29. As of February 26, 2008 the renamed BRUKER CORPORATION has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group Bruker Corporation now operates in two segments the life science and analytical (LSA) systems segment and the international advanced superconductor (IAS) segment. Bruker has a market cap of $1.2 billion; its shares were traded at around $7.29 with a P/E ratio of 15.5 and P/S ratio of 1.1.
Bruker recently reported its first quarter 2009 results. The company announced that its xGAAP net income for the first quarter of 2009 was $8.4 million, or 5 cents per diluted share, compared to a net loss of ($0.8) million, or 0 cents per diluted share, in the first quarter of 2008. Frank Laukien, President and CEO, commented: “We are pleased with our first quarter 2009 results, given the challenges in the marketplace today. During the first quarter, while we saw softness in our industrial and pharma/biotech orders, we recorded healthy orders from academic, medical school, government and other non-profit customers, which typically account for about two-thirds of Bruker’s revenue. While we continue to be below our gross margin and operating margin goals, we have started to see the effects of our cost-cutting initiatives and we expect to realize further savings in 2009. We continue to rationalize our cost structure, but we also are investing in new opportunities, and have introduced a record number of important new products so far in 2009.”
Bruker's CFO increased his position in the company, while another insider lowered his. CFO William J Knight bought 5,000 shares of BRKR stock on 11/20/2008 at the average price of $3.73. 10% Owner Marc M Laukien sold 2,100,000 shares of BRKR stock on 05/07/2009 at the average price of $6.91; the price of the stock has increased by 5.5% since.
Verizon Communications Inc. (VZ): EVP and Pres. & CEO - VZW JV Lowell C Mcadam Bought 16,700 Shares
EVP and Pres. & CEO - VZW JV of Verizon Communications Inc. (VZ) Lowell C Mcadam bought 16,700 shares on 05/06/2009 at an average price of $29.85. Verizon Communications formed by the merger of Bell Atlantic and GTE is one of the world's leading providers of high-growth communications services. Verizon companies are the largest providers of wireline and wireless communications in the United States. Verizon is also the world's largest provider of print and on-line directory information. Verizon Communications Inc. has a market cap of $84.77 billion; its shares were traded at around $29.85 with a P/E ratio of 11.6 and P/S ratio of 0.9. The dividend yield of Verizon Communications Inc. stocks is 6.2%. Verizon Communications Inc. had an annual average earning growth of 2.4% over the past 10 years. GuruFocus rated Verizon Communications Inc. the business predictability rank of 4-star.
Verizon recently reported its 1 st quarter 2009 results. The company announced that its diluted earnings per share was 58 cents per share, compared to 57 cents per share a year ago. The company's total revenues grew 11.6%. "Our business groups executed with excellence in the first quarter," said Verizon Chairman and CEO Ivan Seidenberg. "Our operational and financial discipline produced continued revenue and earnings growth, as well as an expansion of our already strong operating cash flows. A highlight of the quarter was our successful completion of the Alltel acquisition. We quickly began integration efforts, and we are aggressively pursuing synergies."
Brian Rogers owns 5,223,000 shares as of 03/31/2009. Tweedy Browne owns 11,418 shares as of 12/31/2008. Kenneth Fisher owns 581,660 shares as of 12/31/2008, a decrease of 25.96% of from the previous quarter. Mark Hillman owns 573,251 shares as of 12/31/2008, a decrease of 33.47% of from the previous quarter. Richard Aster Jr owns 626,000 shares as of 03/31/2009, a decrease of 39.95% of from the previous quarter. George Soros owns 10,000 shares as of 12/31/2008, a decrease of 75% of from the previous quarter.
Two other insiders have also increased their positions in the company. EVP & Chief Technology Officer Richard J. Lynch bought 2,000 shares, while President of Verizon Business John F Killian bought 7,500 shares of VZ stock.
Angiotech Pharmaceuticals Inc. (ANPI): President & CEO William L Hunter Bought 634,551 Shares
President & CEO of Angiotech Pharmaceuticals Inc. (ANPI) William L Hunter bought 634,551 shares during the past week at an average price of $0.68. Angiotech Pharmaceuticals Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of the anticancer drug paclitaxel. The company has a market cap of $58 million; its shares were traded at around $0.68 with and P/S ratio of 0.2.
Angiotech Pharmaceuticals recently reported its first quarter 2009 results. The company announced that its total revenue was $88.3 million, and net product sales were $46.1 million. “We were pleased to post solid results for our first quarter in what has been a difficult business environment for many companies,” said Dr. William Hunter, President and CEO of Angiotech. “Sales in our proprietary Surgical and Interventional business areas continued to show very promising growth, with Quill SRS in particular garnering greater acceptance in new hospitals and surgical disciplines, and we continued to realize
expense reductions as compared to the prior quarter. Additionally, our royalty revenue increased as compared to the fourth quarter of last year, indicating an improved market position for our partner Boston Scientific and higher sales of paclitaxel-eluting stents.”
Other insiders are increasing their positions in the company, including 10% Owner Coast Asset Management In West, Director Hartley T Richardson, and Director David T Howard
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
